Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
Twelve hospitals across India will be part of the network which will support the trial in India
IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023
Experts’ conclave to pave holistic approach to cancer management
The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
Having a healthy gut is key as it permits the body to build a stronger immune system
Subscribe To Our Newsletter & Stay Updated
